SGEN Seattle Genetics Inc.

0  0%
Previous Close 72.38
Price To Book 8.89
Market Cap 11,675,952,413
Shares 161,314,623
Volume 0
Short Ratio
Av. Daily Volume 731,213

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated.
Neoadjuvant for newly diagnosed Stage 2 or 3 HER2 negative breast cancer
Phase 1/2 trial initiated early 2018.
First-line triple negative breast cancer (TNBC)
Phase 2 completion of enrolment announced March 29, 2019.
Tisotumab Vedotin (innovaTV 204 )
Cervical Cancer
Phase 2 pivotal data noted 44% ORR. CR rate 12%. BLA filing due 2019.
Enfortumab vedotin - EV201
Urothelial cancer
Phase 3 trial initiated 2Q 2017.
ADCETRIS and Opdivo
Relapsed Hodgkin Lymphoma
Phase 3 trial initiated mid-2017. Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
ADCETRIS and Opdivo CM-812
Relapsed Hodgkin Lymphoma
Approval announced August 19, 2011.
Hodgkin lymphoma and Anaplastic large cell lymphoma
Phase 1/2 clinical hold placed on December 27, 2016 was lifted March 6, 2017. Enrollment halted June 19, 2017 due to safety.
Vadastuximab Talirine (SGN-CD33A)
Myelodysplastic syndrome (MDS)
Phase 1b updated data at SABCS December 7, 2017.
(Tucatinib ONT-380) and T-DM1
HER2+ Metastatic Breast Cancer (MBC)
Phase 2 data due 2019.
(Tucatinib ONT-380) + Herceptin and Xeloda - HER2CLIMB trial
HER2+ Metastatic Breast Cancer (MBC)
Phase 3 trial discontinued due to higher rate of deaths - June 19, 2017.
Vadastuximab Talirine (CASCADE)
Acute myeloid leukemia (AML) - cancer
sBLA approval announced March 20, 2018. PDUFA date under priority review was May 1, 2018.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
Frontline DLBCL cancer
FDA Approval announced November 16, 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Approved August 17, 2015 under priority review.
Post-transplant Hodgkin lymphoma (HL) cancer
Approval announced November 9, 2017.
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma
Phase 1b trial has been initiated - noted February 6, 2018.
Enfortumab vedotin and pembrolizumab
2nd-line Urothelial cancer
Phase 1b/2 trial has been initiated.
Ladiratuzumab Vedotin
Triple negative breast cancer (TNBC)
Phase 3 trial initiation announced July 9, 2018.
Enfortumab vedotin - EV-301
Urothelial cancer
Phase 2 dosing has commenced - noted July 12, 2018.
Tisotumab Vedotin (innovaTV 207)
Solid tumors
Phase 1/2 updated data presented at ESMO October 20. 2018.
Tisotumab Vedotin (innovaTV 201)
Recurrent Cervical Cancer
Phase 1 data February 11, 2019 noted ORR 42%.
Enfortumab vedotin EV-101
Urothelial cancer
FDA approval announced June 10, 2019.
Polatuzumab vedotin and bendamustine plus Rituxan (rituximab)
Diffuse large B-cell lymphoma (DLBCL)
Phase 2 presentation at EHA June 15, 2019.
ADCETRIS and Opdivo CM-744
Relapsed/Refractory Classical Hodgkin Lymphoma

Latest News

  1. Here’s What Hedge Funds Think About Seattle Genetics, Inc. (SGEN)
  2. See what the IHS Markit Score report has to say about Seattle Genetics Inc.
  3. Roche's Rozlytrek Gets Approval in Japan for Solid Tumors
  4. Does Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Salary Compare Well With Others?
  5. Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML)
  6. Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
  7. Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA
  8. Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
  9. Who Are The Winners And Losers From The Year's Biggest Cancer Meeting?
  10. Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study
  11. Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study
  12. Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS® (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting
  13. Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
  14. Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
  15. The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace
  16. Revealed: PSBJ inaugural Middle Market Fast 50 list makers
  17. Seattle Genetics (SGEN) Down 2.7% Since Last Earnings Report: Can It Rebound?
  18. Seattle Genetics Appoints Robin Taylor, Ph.D., Chief Commercial Officer